RxDoctor Payments Data

Pamela Allen, MD

Hematology & Oncology · Atlanta, GANPI 1376868836

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,645 of the $40,378 with a category attached, or 88.3%. 14 manufacturers reported payments, led by Seagen Inc. at 26.4% of the total. Reporting peaked in 2020 at $12,727 and has fallen 52.5% since, to $6,044 in 2025.

$40,378in general payments, 2019–2025

Across 50 payments — averaging $807.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$11K
  • Kyowa Kirin, Inc.$9K
  • Daiichi Sankyo Inc.$6K
  • Imbrium Therapeutics L.p.$6K
  • Secura Bio, Inc.$4K
  • Acrotech Biopharma Inc.$3K
  • plus $2K from 8 others
$530,179in research payments, 2019–2025

Across 188 payments — averaging $2820.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$235K
  • Eisai Inc.$105K
  • Merck$95K
  • Bristol Myers Squibb$42K
  • Otsuka Pharmaceutical Co., Ltd.$27K
  • Secura Bio, Inc.$15K
  • plus $11K from 3 others

What the payments were for

  • Consulting fees$35,64588%
  • Speaking & faculty fees$1,4754%
  • Travel & lodging$1,1603%
  • Food & beverage$2,0985%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,378 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$9,619
Medicare patients
49
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BesremiRopeginterferon Alfa-2b-Njft11$186,263
CalquenceAcalabrutinib Maleate12$186,223
ImbruvicaIbrutinib12$173,062
BrukinsaZanubrutinib12$93,491
PegasysPeginterferon Alfa-2a13$54,424
ValacyclovirValacyclovir Hcl33$1,197
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$72$93,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →